$264 Million is the total value of Decheng Capital Management III (Cayman), LLC's 25 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZNTL | New | Zentalis Pharmaceuticals Inc. | $51,271,000 | – | 1,824,583 | +100.0% | 19.44% | – |
| ALPN | Alpine Immune Sciences, Inc. | $40,068,000 | -5.1% | 4,708,288 | 0.0% | 15.19% | +17.4% | |
| Cue Health Inc. | $28,739,000 | -50.4% | 8,980,909 | 0.0% | 10.90% | -38.6% | ||
| ILMN | Illumnia, Inc. | $28,435,000 | -47.2% | 154,238 | 0.0% | 10.78% | -34.7% | |
| RCUS | Arcus BioSciences, Inc. | $22,040,000 | -19.7% | 869,790 | 0.0% | 8.36% | -0.7% | |
| TXG | 10x Genomics, Inc. | $13,755,000 | -40.5% | 303,984 | 0.0% | 5.22% | -26.4% | |
| ALBO | Albireo Pharma, Inc. | $10,294,000 | -33.4% | 518,342 | 0.0% | 3.90% | -17.6% | |
| EQ | Equillium Inc. | $9,073,000 | -35.2% | 4,447,308 | 0.0% | 3.44% | -19.9% | |
| ACET | Adicet Bio, Inc. | $8,468,000 | -26.9% | 580,000 | 0.0% | 3.21% | -9.5% | |
| BYSI | BeyondSpring Inc. | $7,140,000 | -34.5% | 4,958,142 | 0.0% | 2.71% | -19.0% | |
| RXDX | Prometheus Biosciences, Inc. | $7,058,000 | -25.2% | 250,000 | 0.0% | 2.68% | -7.5% | |
| Aadi Bioscience, Inc. | $6,484,000 | -27.4% | 526,329 | 0.0% | 2.46% | -10.2% | ||
| PACB | Pacific Biosciences of California, Inc. | $6,470,000 | -51.4% | 1,463,872 | 0.0% | 2.45% | -39.9% | |
| HZNP | New | Horizon Therapeutics PLC | $4,419,000 | – | 55,400 | +100.0% | 1.68% | – |
| Sema4 Holings Corp. | $4,308,000 | -59.0% | 3,418,929 | 0.0% | 1.63% | -49.2% | ||
| MRSN | Mersana Therapeutics, Inc. | $4,178,000 | +15.8% | 904,268 | 0.0% | 1.58% | +43.2% | |
| Aura Biosciences, Inc. | $2,976,000 | -35.6% | 210,000 | 0.0% | 1.13% | -20.3% | ||
| AtriCure Inc. | $1,890,000 | -37.8% | 46,259 | 0.0% | 0.72% | -23.0% | ||
| TERN | Terns Pharmaceuticals, Inc. | $1,771,000 | -16.5% | 714,285 | 0.0% | 0.67% | +3.2% | |
| Owlet, Inc. | $1,527,000 | -61.8% | 898,400 | 0.0% | 0.58% | -52.7% | ||
| NBSE | NeuBase Therapeutics, Inc. | $1,050,000 | -44.1% | 1,000,000 | 0.0% | 0.40% | -30.9% | |
| SCYX | Scynexis Inc. | $1,033,000 | -52.4% | 555,555 | 0.0% | 0.39% | -41.1% | |
| NAUT | Nautilus Biotechnology, Inc. | $807,000 | -38.0% | 300,000 | 0.0% | 0.31% | -23.3% | |
| MASS | 908 Devices Inc. | $412,000 | +8.4% | 20,000 | 0.0% | 0.16% | +34.5% | |
| OMIC | Singular Genomics Systems, Inc. | $76,000 | -39.7% | 20,000 | 0.0% | 0.03% | -25.6% | |
| CMPI | Exit | Checkmate Pharamaceuticals, Inc. | $0 | – | -1,333,254 | -100.0% | -1.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.